Drug intelligence / Profile preview

ATUX-1215

Development stage: Preclinical
Lead developer: Atux Iskay
Modality: Small Molecules
Administration: Oral

Overview

ATUX-1215 is a small molecule activator of Protein Phosphatase 2A (PP2A) currently under investigation for the treatment of high-risk neuroblastoma (NBL). It functions by reactivating PP2A, which subsequently leads to the dephosphorylation of MYCN, BRD4, and RNA Polymerase II. This mechanism suppresses MYCN expression and stability and modulates histone acetylation (specifically H3K27ac and H3ac). Research indicates that ATUX-1215 treatment upregulates the fibrinogen alpha chain (FGA) gene, a marker associated with improved overall survival in MYCN-amplified and stage 4 neuroblastoma patients.

Targets

PP2A (Protein phosphatase 2A)

Beyond the preview

Go deeper on ATUX-1215.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATUX-1215.

Explore the full profile